Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Journal: Clinical lymphoma, myeloma & leukemia
PMID: 26795075

Abstract

INTRODUCTION: The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients with multiple myeloma (MM) and renal impairment.

Authors

  • Jesus Berdeja
    Sarah Cannon Research Institute, Nashville, TN. Electronic address: jberdeja@tnonc.com.
  • Sundar Jagannath
    Mount Sinai Hospital, New York, NY.
  • Jeffrey Zonder
    Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Ashraf Badros
    University of Maryland, Baltimore, MD.
  • Jonathan L Kaufman
    Winship Cancer Institute, Emory University, Atlanta, GA.
  • Robert Manges
    Investigative Clinical Research of Indiana, Indianapolis, IN.
  • Manish Gupta
    Bristol-Myers Squibb, Princeton, NJ.
  • Amol Tendolkar
    Bristol-Myers Squibb, Princeton, NJ.
  • Mark Lynch
    Bristol-Myers Squibb, Wallingford, CT.
  • Eric Bleickardt
    Bristol-Myers Squibb, Wallingford, CT.
  • Prashni Paliwal
    Bristol-Myers Squibb, Wallingford, CT.
  • Ravi Vij
    Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.

Keywords

External Resources

Popular Topics
Recent Journals